Aldeyra seeks FDA review division transfer for ADX-2191 lymphoma treatment

• Aldeyra Therapeutics on November 9, 2026, requested FDA review of ADX-2191 for primary vitreoretinal lymphoma move to its hematologic malignancies division.
• The company withdrew its previously agreed Special Protocol Assessment protocol, relinquishing FDA agreement on the planned trial’s design and analysis.
• The planned trial is not expected to begin while the jurisdictional request is pending; any transfer remains at the FDA’s discretion.
• A new review division would not be bound by prior agreements and could require additional trials, potentially delaying or preventing approval.
• Regulatory uncertainty could increase costs, shorten the cash runway and require additional capital sooner than expected.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aldeyra Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-453537), on November 09, 2026, and is solely responsible for the information contained therein.